Article
Effect of food and polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers.
British journal of clinical pharmacology - 1 Jan 2024
Hu Yixin, Wu Jianyuan, Cheng Bingyu, You Rongli, Yin Xueyan, Chen Guiying, Yang Ling, Zhang Yang, Si Luqin, Jiang Hongliang, Zhang Yongjun, Huang Jianying, Huang Jiangeng
Abstract excerpt
AIMS: Abiraterone acetate, a prodrug of abiraterone (ABI), provides an efficient therapeutic option for metastatic castration-resistant prostate cancer patients. ABI undergoes extensive metabolism in vivo and is transformed into active metabolites Δ4 -abiraterone and 3-keto-5α-abiraterone as well as inactive metabolites abiraterone sulfate and abiraterone N-oxide sulfate. We aimed to examine the effect of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
